125 related articles for article (PubMed ID: 36741922)
21. The prospect of precision therapy for renal cell carcinoma.
Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
[TBL] [Abstract][Full Text] [Related]
22. Using Genomic and Transcriptome Analyses to Identify the Role of the Oxidative Stress Pathway in Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance.
Che X; Qi X; Xu Y; Wang Q; Wu G
Oxid Med Cell Longev; 2021; 2021():5561124. PubMed ID: 34721758
[TBL] [Abstract][Full Text] [Related]
23. Cyclovirobuxine inhibits the progression of clear cell renal cell carcinoma by suppressing the IGFBP3-AKT/STAT3/MAPK-Snail signalling pathway.
Liu Y; Lv H; Li X; Liu J; Chen S; Chen Y; Jin Y; An R; Yu S; Wang Z
Int J Biol Sci; 2021; 17(13):3522-3537. PubMed ID: 34512163
[TBL] [Abstract][Full Text] [Related]
24. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
[TBL] [Abstract][Full Text] [Related]
25. Low NR3C2 levels correlate with aggressive features and poor prognosis in non-distant metastatic clear-cell renal cell carcinoma.
Zhao Z; Zhang M; Duan X; Deng T; Qiu H; Zeng G
J Cell Physiol; 2018 Oct; 233(10):6825-6838. PubMed ID: 29693713
[TBL] [Abstract][Full Text] [Related]
26. MiR-31-5p acts as a tumor suppressor in renal cell carcinoma by targeting cyclin-dependent kinase 1 (CDK1).
Li Y; Quan J; Chen F; Pan X; Zhuang C; Xiong T; Zhuang C; Li J; Huang X; Ye J; Zhang F; Zhang Z; Gui Y
Biomed Pharmacother; 2019 Mar; 111():517-526. PubMed ID: 30597305
[TBL] [Abstract][Full Text] [Related]
27. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
Su D; Singer EA; Srinivasan R
Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
[TBL] [Abstract][Full Text] [Related]
28. Integrative bioinformatics analysis of a prognostic index and immunotherapeutic targets in renal cell carcinoma.
Tao H; Li Z; Mei Y; Li X; Lou H; Dong L; Zhou L
Int Immunopharmacol; 2020 Oct; 87():106832. PubMed ID: 32738597
[TBL] [Abstract][Full Text] [Related]
29. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification.
Li Y; Chu F; Li P; Johnson N; Li T; Wang Y; An R; Wu D; Chen J; Su Z; Gu X; Ding X
J Ethnopharmacol; 2021 May; 271():113854. PubMed ID: 33513419
[TBL] [Abstract][Full Text] [Related]
30. Identification of small molecule drugs and development of a novel autophagy-related prognostic signature for kidney renal clear cell carcinoma.
Xing Q; Ji C; Zhu B; Cong R; Wang Y
Cancer Med; 2020 Oct; 9(19):7034-7051. PubMed ID: 32780567
[TBL] [Abstract][Full Text] [Related]
31. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
32. BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma.
Wan P; Chen Z; Zhong W; Jiang H; Huang Z; Peng D; He Q; Chen N
Oncol Rep; 2020 Dec; 44(6):2475-2486. PubMed ID: 33125143
[TBL] [Abstract][Full Text] [Related]
33. A network pharmacology approach to explore active compounds and pharmacological mechanisms of a patented Chinese herbal medicine in the treatment of endometriosis.
Wu Y; Zhu Y; Xie N; Wang H; Wang F; Zhou J; Qu F
PLoS One; 2022; 17(2):e0263614. PubMed ID: 35130311
[TBL] [Abstract][Full Text] [Related]
34. Network Pharmacology-Based and Clinically Relevant Prediction of the Potential Targets of Chinese Herbs in Ovarian Cancer Patients.
Sun J; Liu J; Liu D; Wu X
Biomed Res Int; 2020; 2020():8965459. PubMed ID: 33150184
[TBL] [Abstract][Full Text] [Related]
35. Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression.
Wang J; Xu Y; Zhu L; Zou Y; Kong W; Dong B; Huang J; Chen Y; Xue W; Huang Y; Zhang J
J Cancer Res Clin Oncol; 2018 Jan; 144(1):39-52. PubMed ID: 28993942
[TBL] [Abstract][Full Text] [Related]
36. Based on Network Pharmacology to Explore the Molecular Targets and Mechanisms of Gegen Qinlian Decoction for the Treatment of Ulcerative Colitis.
Wei M; Li H; Li Q; Qiao Y; Ma Q; Xie R; Wang R; Liu Y; Wei C; Li B; Zheng C; Sun B; Yu B
Biomed Res Int; 2020; 2020():5217405. PubMed ID: 33299870
[TBL] [Abstract][Full Text] [Related]
37. The emerging role of nuclear factor kappa B in renal cell carcinoma.
Morais C; Gobe G; Johnson DW; Healy H
Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
[TBL] [Abstract][Full Text] [Related]
38. Chinese herbal medicine promote tissue differentiation in colorectal cancer by activating HSD11B2.
Qi L; Zhang Y; Song F; Ding Y
Arch Biochem Biophys; 2020 Nov; 695():108644. PubMed ID: 33098869
[TBL] [Abstract][Full Text] [Related]
39. [Identification of traditional Chinese drugs containing active ingredients for treating myocardial infarction and analysis of their therapeutic mechanisms by network pharmacology and molecular docking].
Zhao S; Liu K; Duan J; Tao X; Li W; Bai Y; Wei P; Xi M; Yang H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jan; 42(1):13-25. PubMed ID: 35249866
[TBL] [Abstract][Full Text] [Related]
40. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
